Lacosamida Viso Farmacéutica (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilises hyperexcitable neurons and reduces repetitive firing, thereby lowering the likelihood of seizure propagation in focal epilepsy. Its selective action on the persistent sodium current distinguishes it from traditional fast‑inactivation blockers.

The dosage of lacosamide is individualized and set by the prescribing healthcare professional. The prescriber determines the appropriate amount based on the patient’s age, weight, renal and hepatic function, concomitant medications, and clinical response, following local prescribing guidelines.

Lacosamide’s pregnancy category is not definitively established. It should be used during pregnancy only when the potential benefit to the mother outweighs any possible risk to the fetus. Limited data are available for breastfeeding; a decision should be made after weighing the infant’s exposure against maternal therapeutic need.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lacosamida Viso Farmacéutica. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional sodium‑channel blockers such as carbamazepine, lacosamide targets the slow inactivation phase of the channel, offering a complementary mechanism that may be better tolerated in some patients. It generally has a lower risk of drug‑induced hyponatremia but shares similar CNS‑depressant potential when combined with other antiepileptics.

Store the product at room temperature, below 25 °C, in its original packaging. Protect it from moisture, excessive heat and direct sunlight. Ensure the container is tightly closed to maintain stability, and keep it out of reach of children.

Lacosamida Viso Farmacéutica is supplied as oral tablets intended for swallowing whole with water. It may be taken with or without food, according to the prescriber’s instructions. Patients should not crush, chew, or split the tablets unless specifically advised.

Serious risks include the potential for suicidal thoughts or behavior, severe skin reactions such as Stevens‑Johnson syndrome, cardiac conduction abnormalities (notably PR‑interval prolongation), and rare anaphylactic reactions. Prompt medical attention is required if any of these events are suspected.

Lacosamide is contraindicated in individuals with known hypersensitivity to lacosamide or any of its excipients. Patients with significant cardiac conduction disorders, such as advanced atrioventricular block without a pacemaker, should avoid its use. Caution is also advised for those with severe renal or hepatic impairment, and it should be prescribed only after careful assessment.